Overview

Neoadjuvant Concomitant Modulated Electro-hyperthermia in HER2-negative Breast Cancer

Status:
Recruiting
Trial end date:
2025-04-30
Target enrollment:
Participant gender:
Summary
The aim of this study is to investigate whether the application of concomitant modulated electro-hyperthermia in a neoadjuvant chemotherapeutic setting is beneficial for patients with HER2-negative, stage II-III breast cancer.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Semmelweis University
Treatments:
Carboplatin
Cyclophosphamide
Doxorubicin
Paclitaxel